10 FEBRUARY 2021
Targeting both RNA and the proteins that interact with it has become one of the hottest new areas in drug discovery. Biotechs such as Storm Therapeutics, 28-7, Gotham Therapeutics and Accent Therapeutics amongst many others, are all developing small molecule inhibitors of misregulated epigenetic processes.
On February 10th at 11am EST ZoBio will organize together with Cambridge Healthtech Institute the webinar: “Epitranscriptomics and Disease: The Role of RNA Modification in the Life Cycle of the Cell”. During the webinar two of the top experts in the field: Richard I. Gregory, Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Samie R. Jaffrey, the Greenberg-Starr Professor in the Department of Pharmacology at the Weill Cornell Medical College will highlight an exciting developments on RNA modifications and epitranscriptomics.
Both key opinion leaders will share their insights into the mechanisms of epitranscriptomics and its relationship to disease, in particular oncology. They will describe their latest findings on important targets and the biological outcome of inhibiting them. In addition, ZoBio will share a case study on development of small molecule inhibitors of an epitranscriptomic target. In all, the webinar will bring you insights into the field, the propsects for drug discovery and what it takes to be successful if you chose to pursue it.
Register via the Online Registration form in order to receive the access credentials to the Webinar.
We hope you are as excited about this webinar as we are!
25 NOVEMBER 2020
Marta Carneiro, Head of Structural Biology at ZoBio, presented the lecture ‘NMR in target driven drug discovery: why not?’ on Wednesday 25 November 2020. Marta has discussed several examples of how ZoBio uses NMR in various ways to streamline the discovery process and reduce downstream attrition. This talk was a part of the Drug Discovery/Development session of the ICMRBS Early Career Researcher Webinar Series. The webinars are specifically meant for early researchers working on magnetic resonance in biological systems, but also for more senior scientists that may be interested in information about different NMR approaches in drug discovery.
16-18 SEPTEMBER 2020
As in the previous years ZoBio participated as a sponsor in Discovery on Target, the industry’s preeminent event on novel drug targets and technologies for drug discovery professionals. The conference highlighted advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.
Gregg Siegal presented the lecture: ‘Targeting RNA Readers’ on Wednesday September 16. In his presentation Gregg has shared insights of a developing inhibitors of YTHDF2, a protein that selectively recognized 6 methyl-adenosine in mRNA thereby regulates protein expression. Results from fragment screening and hit evolution campaign were presented.